T Shimamoto. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitorsAnimalsAorta/pathologyAorta/physiologyArteries/drug effectsArteries/physiologyArteriosclerosis/etiologyArteriosclerosis/therapyBiological Transport/drug effectsBlood Coagulation/drug effectsBlood Platelets/physiologyChylomicrons/metabolismEndothelium/drug effectsEndothelium/physiologyEnzyme Inhibitors/therapeutic useHumansLipoproteins, HDL/metabolismLipoproteins, LDL/metabolismLipoproteins, VLDL/metabolismPhosphodiesterase InhibitorsPlatelet AggregationPyridinolcarbamate/therapeutic useStructure-Activity Relationship
Substances: See more » ChylomicronsEnzyme InhibitorsLipoproteins, HDLLipoproteins, LDLLipoproteins, VLDLPhosphodiesterase InhibitorsPyridinolcarbamate3',5'-Cyclic-AMP Phosphodiesterases
Year: 1975 PMID: 167561 DOI: 10.1007/978-1-4615-9029-3_6
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622